Mineralocorticoid Receptor

Related Products

Mineralocorticoid receptor (MR) is an intracellular steroid hormone receptor, and a member of the nuclear receptor superfamily, that mediates the physiological action of two important adrenal steroids, aldosterone and cortisol. Mineralocorticoid receptor is closely related to the glucocorticoid receptor (GR), and it can indifferently bind mineralocorticoid and glucocorticoid hormones. Activation of the mineralocorticoid receptor in the distal nephron by its ligand, aldosterone, plays an important role in sodium reabsorption and blood pressure regulation. Besides the regulation of sodium balance and the control of blood pressure, aldosterone-human mineralocorticoid receptor tandem also exerts important regulatory functions on the cardiovascular and central nervous systems.

Mineralocorticoid receptor participates in the regulation of hydroelectrolytic homeostasis in sodium-transporting tight epithelia such as distal nephron, colon, lung, and salivary and sweat glands. In such epithelial target cells, the mineralocorticoid specificity of aldosterone action is given by the enzyme 11β-hydroxysteroid dehydrogenase 2 (11-HSD2), which converts active glucocorticoids into inactive metabolites. Mineralocorticoid receptor is also expressed in nonepithelial tissues such as the heart, some areas of the brain, large blood vessels, and mononuclear leukocytes. The ligand-activated mineralocorticoid receptor is translocated in the nucleus and acts as a transcription factor after its interaction with the consensus glucocorticoid response element (GRE) sequences. Mineralocorticoid receptor could activate or inhibit transcription of target genes whose identification is under intense investigation.

Mineralocorticoid Receptor Related Products (47):

By Effects:	Inhibitors (7) Agonists (10) Antagonists (25) Modulator (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-111372

Finerenone	Antagonist	99.66%
Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease.

HY-B0561

Spironolactone	Antagonist	99.66%
Spironolactone is an aldosterone antagonist that acts on the aldosterone mineralocorticoid receptor (IC₅₀=24 nM) and androgen receptor (IC₅₀=77 nM), promotes podocyte autophagy and regulates pain. Spironolactone improves hypertension-related vascular hypertrophy and remodeling by reducing angiotensin II (AngⅡ)-induced inflammation, reduces aldosterone-induced vascular and soft tissue calcification through PIT1-dependent signaling, and alleviates vascular dysfunction in type Ⅱ diabetic mice by reducing oxidative stress and restoring NO/GC signaling; at low concentrations, it and its metabolites can interfere with aldosterone biosynthesis in the adrenal cortex and inhibit voltage-dependent Ca²⁺ channels to exert antihypertensive effects.

HY-113414

Deoxycorticosterone	Agonist	99.90%
Deoxycorticosterone is a steroid hormone produced by the adrenal gland that possesses mineralocorticoid activity and acts as an aldosterone precursor. Deoxycorticosterone is an agonist for O. mykiss mineralocorticoid receptor (rtMR) transcription with EC₅₀ of 0.16 nM. Deoxycorticosterone could acts as an immune stimulator in fish.

HY-100471

Esaxerenone	Antagonist	99.93%
Esaxerenone (CS-3150) is a highly potent and selective non-steroidal mineralocorticoid receptor antagonist.

HY-109017

Vamorolone	Antagonist	99.10%
Vamorolone (VBP15) is a first-in-class, orally active dissociative steroidal anti-inflammatory agent and membrane-stabilizer. Vamorolone improves muscular dystrophy without side effects. Vamorolone shows potent NF-κB inhibition and substantially reduces hormonal effects.

HY-B1203R

Fludrocortisone (Standard)	Agonist
Fludrocortisone (Standard) is the analytical standard of Fludrocortisone. This product is intended for research and analytical applications. 0

HY-107917R

Desoxycorticosterone pivalate (Standard)
Desoxycorticosterone pivalate (Standard) is the analytical standard of Desoxycorticosterone pivalate. This product is intended for research and analytical applications. Desoxycorticosterone pivalate (DOCP) is a mineralocorticoid hormone and an analog of Desoxycorticosterone. Desoxycorticosterone pivalate is used for the management of canine hypoadrenocorticism.

HY-163689

Vicadrostat
Vicadrostat is an aldosterone synthase inhibitor (IC₅₀=48 nM). Vicadrostat can be used for research in kidney diseases and cardiovascular diseases.

HY-B0251

Eplerenone	Antagonist	99.81%
Eplerenone (Epoxymexrenone) is a selective, highly specific and orally active aldosterone blocker (SAB). Eplerenone also is a selective mineralocorticoid receptor antagonist (MRA) with IC₅₀ value of 0.081 μM. Eplerenone can be used for the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV).

HY-B1472

Deoxycorticosterone acetate	Agonist	99.57%
Deoxycorticosterone acetate (DOCA) is an adrenocortin, acts as a precursor to aldosterone. Deoxycorticosterone acetate is a mineralocorticoid receptor agonist. Deoxycorticosterone acetate can cause severe renal injury, including inflammation, fibrosis, glomerular damage, and proteinuria.

HY-B1203A

Fludrocortisone acetate	Agonist	99.37%
Fludrocortisone acetate (9α-Fludrocortisone acetate) is a synthetic mineralocorticoid with potential use in Addison's disease to reduce urinary sodium loss and to increase blood pressure.

HY-132809

Baxdrostat	Inhibitor	99.60%
Baxdrostat is a aldosterone synthase inhibitor.

HY-16276

Osilodrostat	Inhibitor	99.90%
Osilodrostat (LCI699) is a potent, orally active11β-hydroxylase (CYP11B1) inhibitor with an IC₅₀ value of 35 nM. Osilodrostat is a potent, orally aldosterone synthase (CYP11B2) inhibitor with IC₅₀ values of 0.7 nM and 160 nM for human aldosterone synthase and rat aldosterone synthase, respectively. Osilodrostat inhibits aldosterone and corticosterone synthesis. Osilodrostat has blood pressure lowering ability. Osilodrostat can be used for research of Cushing syndrome (CS).

HY-B1438

Canrenone	Antagonist	99.56%
Canrenone (Aldadiene) is an aldosterone antagonist extensively used as a diuretic agent.

HY-147277

Lorundrostat	Inhibitor	99.37%
Lorundrostat (MT-4129) is an orally active aldosterone synthase inhibitor. Lorundrostat can be used in studies of high blood pressure.

HY-109002

Apararenone	Antagonist	99.09%
Apararenone (MT-3995) is a novel non-steroidal mineralocorticoid receptor antagonists under development for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis.

HY-B1203

Fludrocortisone	Agonist	98.97%
Fludrocortisone, a synthetic mineralocorticoid with anti-inflammatory activity.

HY-150701

INCB13739	Inhibitor	99.79%
INCB13739 is an orally active, potent, selective and tissue-specific11β-HSD1 (11β-hydroxysteroid dehydrogenase 1) inhibitor, with IC₅₀ values of 3.2 nM (11β-HSD1 enzymatic) and 1.1 nM (11β-HSD1 PBMC), respectively. INCB13739 can be used for type 2 diabetes mellitus (T2DM) and obesity research.

HY-120274

Balcinrenone	Modulator	99.96%
Balcinrenone (AZD9977) is a potent, selective, and orally active mineralocorticoid receptor (MR) modulator. Balcinrenone is used for heart failure, and chronic kidney disease research.

HY-B1582A

Canrenoate potassium	Antagonist	99.89%
Canrenoate (Aldadiene) potassium, a proagent that releases canrenone, is a potent, competitive mineralocorticoid receptor (aldosterone receptor) antagonist. Potassium canrenoate, as a diuretic, is used for the research of hypertension.

Name
Email *

	Sorry, but the email address you supplied was invalid.